Turn Therapeutics
Market cap $261M 30.6M shares (10-Q, Nov 6, 2026) × $8.55 close Nov 17, 2026
Most recent annual filing: 2026-03-31
- GX-03 eczema Ph2 topline1Q 2027GX-03 eczema Ph2 topline, 1Q 2027, thesis-defining
- GX-03 onychomycosis Ph3 start1Q 2027GX-03 onychomycosis Ph3 start, 1Q 2027, routine
- PermaFusion onychomycosis Ph3 start1Q 2027PermaFusion onychomycosis Ph3 start, 1Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
intranasal influenza vaccine
Technology platforms
PermaFusion · Medline
PermaFusion is an oil-based suspension delivery platform enabling uniform delivery of water-soluble actives without emulsifiers; applications include thermostable intranasal live vaccine stabilization and dermatologic/antifungal product formulations. Focus areas include vaccines and dermatology.
PermaFusion
Multi-patented, API-agnostic topical drug delivery platform enabling stable, emulsifier-free dispersion of active ingredients in oil-based carriers; delivers APIs through skin, nails, and mucous membranes via suspended nanodroplets in petrolatum matrix; compatible with liquid or liquid-soluble APIs including live payloads; focus on dermatological and inflammatory diseases
Capital (as filed)
- Cash
- $9.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$1.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $10.4M cash, runway Q3 2027 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-11-09 S-3 · Shelf registration up to $50.0M aggregate
- 2026-11-09 S-3 · Shelf registration
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (12)
- 2026-11-10 UPDATE: Turn Therapeutics (TTRX) - The Lever Got Pulled 🔒 Paid
- 2026-10-08 UPDATE: Turn Therapeutics (TTRX) - The Binary Slipped a Quarter ★ Distilled Pro
- 2026-09-09 UPDATE: Turn Therapeutics (TTRX) - First a Commissioner, Now a Director 🔒 Paid
- 2026-08-26 UPDATE: Turn Therapeutics (TTRX) - They Finally Sold Some Stock. Just Not to GEM. 🔒 Paid
- 2026-08-19 UPDATE: Turn Therapeutics (TTRX) - GEM Cashed In Its Chips 🔒 Paid
- 2026-08-13 UPDATE: Turn Therapeutics (TTRX) - The GEM Facility Went Untouched 🔒 Paid
- 2026-07-07 UPDATE: Turn Therapeutics (TTRX) - The Vehicle-Response Problem Just Got a Prospective Fix 🔒 Paid
- 2026-06-02 UPDATE: Turn Therapeutics (TTRX) - The Interim Drops, and the Vehicle Arm Did Not Get the Memo 🔒 Paid
- 2026-05-18 UPDATE: Turn Therapeutics (TTRX) - A Former FDA Commissioner Walks Into a Pre-Readout Small-Cap 🔒 Paid
- 2026-05-12 UPDATE: Turn Therapeutics (TTRX) - The Interim Clock Just Moved Up 🔒 Paid
- 2026-03-28 UPDATE: Turn Therapeutics (TTRX) - TTRX Buys Time with a $25M Lifeline... 🔒 Paid
- 2026-03-19 Turn Therapeutics (TTRX) - Scientific Deep Dive for GX-03 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (12 calls)
Every verdict Biotech Distilled has published on Turn Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-19 Watch Turn Therapeutics (TTRX) - Scientific Deep Dive for GX-03 and Pipeline Products Fascinating PermaFusion delivery platform but toxic GEM financing structure and binary Phase 2 readout make it too risky to buy now; wait for data.
- 2026-03-28 Watch UPDATE: Turn Therapeutics (TTRX) - TTRX Buys Time with a $25M Lifeline... Avenue Capital debt extends runway through Phase 2 readout but mortgages the PermaFusion IP and doesn't eliminate GEM dilution risk; stay on sidelines until data.
- 2026-05-12 Watch UPDATE: Turn Therapeutics (TTRX) - The Interim Clock Just Moved Up Interim readout now imminent in Q2 but Phase 3 budget tripled to $60-65M and buying into a binary interim is a speculative trade not an investment; wait for IAC decision.
- 2026-05-18 Watch UPDATE: Turn Therapeutics (TTRX) - A Former FDA Commissioner Walks Into a Pre-Readout Small-Cap Former FDA Commissioner Hahn joining as Executive Clinical and Regulatory Lead is meaningful self-selection and consistent with M&A setup, but stock is up 26% and asymmetric outcomes remain stark; still wait for IAC.
- 2026-06-02 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The Interim Drops, and the Vehicle Arm Did Not Get the Memo PermaFusion delivered measurable vehicle-controlled efficacy in human skin validating the platform, safety stayed clean, and M&A optionality sharpened, though vehicle response is high and Stage 2 enrollment refinement is a flag to monitor.
- 2026-07-07 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The Vehicle-Response Problem Just Got a Prospective Fix PP-NRS≥7 enrichment and Hochberg four-endpoint Stage 2 design address the vehicle-response problem with mechanism-consistent biology, runway extended to Q3 2027, and M&A choreography continues; hold existing positions but new entries at $9.71 are at a richer strike.
- 2026-08-13 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The GEM Facility Went Untouched Zero GEM draws in H1 2026 with only 1.2% share-count growth confirms management restraint; 99.8%-powered Stage 2 design and new HS indication add optionality, but going-concern language and $60-65M Phase 3 gap remain.
- 2026-08-19 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - GEM Cashed In Its Chips GEM's cashless warrant exercise is 1.9% dilution with no cash to company, retiring one overhang but leaving $81M GEM capacity and Phase 3 funding gap intact; a technical supply event not a thesis break.
- 2026-08-26 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - They Finally Sold Some Stock. Just Not to GEM. $1.65M 506(b) private placement to 8 accredited investors with no bank fees is non-punitive and banks 16.5% of the Avenue Tranche 2 equity gate; cumulative dilution ~3.7% over nine months confirms no death spiral.
- 2026-09-09 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - First a Commissioner, Now a Director Former CDC Director Redfield as CSO fits the host-microbe immunology mechanism precisely and strengthens M&A legibility, but the +42.8% move is a credibility re-rating not a data re-rating and the Q4 binary is unchanged.
- 2026-10-08 Speculative buy speculative UPDATE: Turn Therapeutics (TTRX) - The Binary Slipped a Quarter Topline slipped one quarter to Q1 2027 with no explanation, Stage 1 p-values are thin (n=25 enriched subgroup), and Stage 2 is weighted toward low-EASI patients pointing to a narrower label, but trial design and Hochberg structure are unchanged.
- 2026-11-10 Hold UPDATE: Turn Therapeutics (TTRX) - The Lever Got Pulled First GEM draw in eleven months plus a $50M ATM program ends the financing discipline that underpinned the speculative buy; supply overhang into the Q1 2027 binary warrants downgrade to hold, though PJT M&A engagement is the clearest strategic signal yet.
- Long call · opened Jun 2, 2026 at $6.42 · +33.2% vs XBI +13.7% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Topline results from Phase 2b are expected in the first quarter of 2027.”
matched to GX-03 (eczema) · topline data
-
-
-
“We plan to initiate a Phase 2a study to evaluate the safety and efficacy of GX-03 in HS in mid-2027 subject to capital availability.”
matched to GX-03 (eczema) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (44)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Mar 31, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseTurn Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Nov 16, 2026424B5Prospectus supplement (offering)
- Nov 16, 2026424B3Prospectus (resale / update)
- Nov 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED NOVEMBER 10, 2026
- Nov 9, 2026S-3Shelf registration→ BD updateSummary on the 8-K
- Nov 9, 2026S-3Shelf registration→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseTurn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED NOVEMBER 9, 2026→ BD updateThe GEM facility finally fired — a $2.72M draw-down at ~$10/share pricing — and Turn simultaneously filed a $150M shelf + $50M ATM agreement with TD Cowen, while the Q3 10-Q reveals an October 29 GEM draw-down notice and a quietly disclosed PJT Partners strategic advisory engagement ahead of the Q1 2027 topline.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseTurn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
- Oct 21, 2026ReleaseU.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
- Oct 19, 2026DEF 14AProxy statement
- Oct 7, 20268-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED OCTOBER 6, 2026BD extracted 1 program update from this document → TTRX pipeline
- Sep 10, 2026ReleaseTurn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
- Sep 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED SEPTEMBER 10, 2026
- Sep 9, 2026ReleaseTurn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer→ BD updateSummary on the 8-K
- Sep 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED SEPTEMBER 9, 2026→ BD updateFormer CDC Director Robert Redfield joins as Chief Scientific Officer — the second ex-federal health chief added to Turn's leadership in three months, just weeks before the Q4 2026 GX-03 topline that the entire thesis has been building toward.
- Aug 20, 2026ReleaseTurn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and ItchBD extracted 1 program update from this document → TTRX pipeline
- Aug 18, 20268-KCurrent report: unregistered sale of equity
- Aug 17, 20268-KCurrent report: Reg FD disclosure
- Aug 12, 2026ReleaseTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED AUGUST 12, 2026BD extracted 1 program update from this document → TTRX pipeline
- Aug 12, 202610-QQuarterly report
- Jul 28, 2026ReleaseTurn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
- Jul 28, 20268-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED JULY 28, 2026BD extracted 1 program update from this document → TTRX pipeline
- Jul 7, 2026ReleaseTurn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
- Jul 7, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED JULY 7. 2026BD extracted 1 program update from this document → TTRX pipeline
- Jul 6, 2026ReleaseTurn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic DermatitisBD extracted 1 program update from this document → TTRX pipeline
- Jun 3, 20268-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED JUNE 3, 2026BD extracted 1 program update from this document → TTRX pipeline
- Jun 1, 2026ReleaseTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
- Jun 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED JUNE 1, 2026BD extracted 1 program update from this document → TTRX pipeline
- May 27, 2026ReleaseTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
- May 27, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 27, 2026
- May 19, 2026ReleaseTurn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
- May 19, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 19, 2026
- May 18, 2026ReleaseTurn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
- May 18, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 18, 2026
- May 11, 2026ReleaseTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- May 11, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED MAY 11, 2026
- May 11, 202610-QQuarterly report
- Mar 31, 2026ReleaseTurn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
- Mar 31, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED MARCH 31, 2026
- Mar 31, 202610-KAnnual report
- Mar 24, 20268-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1 PRESS RELEASE, DATED MARCH 24, 2026
10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026EFFECTRegistration effective
- Nov 16, 2026EFFECTRegistration effective
- Oct 19, 2026ARSAnnual report to shareholders
- Aug 26, 2026DForm D (exempt offering)→ BD updateTTRX quietly closed a $1.65M Rule 506(b) private placement to 8 accredited investors on August 14 — the first clean equity raise in the coverage history, bypassing both the GEM death-spiral facility and the Avenue debt tranche. It begins chipping away at the $10M equity-raise gate required to unlock Avenue Tranche 2.
- May 13, 2026C-TRC-TR
- Apr 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 2, 2026EFFECTRegistration effective
- Apr 2, 2026EFFECTRegistration effective
- Mar 31, 2026POS AMPost-effective amendment
- Mar 31, 2026POS AMPost-effective amendment